Status:
COMPLETED
A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Dyslipidemia
Eligibility:
All Genders
20-75 years
Phase:
PHASE2
Brief Summary
This study will investigate the effect of MK0859 when administered alone and when in combination with atorvastatin in lowering Low Density Lipoprotein -Cholesterol (LDL-C) in Japanese patients with dy...
Detailed Description
This is the dose ranging study to evaluate efficacy and safety of MK-0859 in Japanese patients. Eligible patients were assigned to 1 of 10 treatment groups (including treatment groups with or without...
Eligibility Criteria
Inclusion
- Patient is male or female and between the ages of 20 and 75 years diagnosed with dyslipidemia
Exclusion
- Patients has Coronary Heart Disease (CHD) or CHD-equivalent disease (except diabetes)
- Patients has uncontrolled diabetes
- Patient is currently participating or has participated in a study with an investigational compound within the last 3 months
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2014
Estimated Enrollment :
408 Patients enrolled
Trial Details
Trial ID
NCT00977288
Start Date
September 1 2009
End Date
April 1 2014
Last Update
May 6 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.